JOIN OUR TEAM

Tag: OTC drugs

Recent Growth Drivers in Analgesics

In what is normally a slow–growing category in the 0.5%-3.0% range for year–over–year performance, the internal analgesics category witnessed much stronger–than–average growth rates in 2020. Consumers stocked up on pain relievers and fever reducers to be prepared for coronavirus. The overall internal analgesics category witnessed sales growth of more than 6.0%, with the Tylenol brand up nearly 40% and Motrin

Know More »
OTC Drugs: U.S. Competitor Cost Structures

Competitive Structure of the U.S. OTC Market Evolving

Recently, the U.S. OTC market has been evolving, boosted by more prescription medications moving along the Rx-to-OTC continuum, as well as a number of changes in the market. Laura Mahecha, Industry Manager of Kline’s Healthcare Practice, reveals more about these changes in a recent interview about the trends and challenges affecting the U.S. OTC market.

Know More »
OTC Market Intelligence

50 Years Old and Still Bounding Over the Counter: Kline’s Healthcare Practice Continues to Deliver Unmatched OTC Market Intelligence

With over half a century of market insights on the U.S. consumer healthcare market, Kline & Company expects that new paradigm shifts in regulations, retail, and technology will create new opportunities for medications to move along the Rx-to-OTC continuum and more growth prospects for the U.S. OTC market. Additionally, with the OTC medication market in

Know More »
FDA Initiative Forms Basis for Healthy Rx-to-OTC Switch Opportunities

FDA Initiative Forms Basis for Healthy Rx-to-OTC Switch Opportunities

In the not so distant past, the U.S. FDA has taken a rather conservative stance concerning Rx-to-OTC switches. Many potential categories have been discounted as not safe and/or effective without a physician’s prescription. This has compelled drug manufacturers to judiciously consider which drugs, if any, they would seek to switch given the necessary multi-million dollar

Know More »
Play Video
Play Video